Attovia Therapeutics files for Nasdaq IPO to fund immune-disease biologics

Why it matters

Attovia's filing shows the biotech IPO window is open enough for platform companies again, but only if public investors accept early clinical data and a long funding road.

Attovia Therapeutics filed for a U.S. IPO on July 14, putting founder and CEO Tao Fu's three-year-old immune-disease biologics company on track for a Nasdaq Global Market listing under the ticker ATTO, Reuters reported.

The real filing is the prospectus. In its S-1, Attovia says it is a clinical-stage biopharmaceutical company headquartered in San Carlos, California, developing biotherapeutics for immune-mediated diseases through its ATTOBODY platform. The preliminary prospectus leaves the economics blank: no offering size, no price range, no share count, no implied valuation and no expected first trading date beyond a planned listing after SEC effectiveness.

That makes the IPO filing less a financing event than a test of whether public investors will buy Attovia's platform story before the company has product revenue, completed clinical trials or an approved drug. Attovia says it has raised $255.8 million since inception from investors including Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives and venBio. The IPO proceeds, together with existing cash, cash equivalents and marketable securities, are earmarked for ATTO-1310, ATTO-2306, the research pipeline including ATTO-1091, other R&D, working capital and general corporate purposes.

Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital are listed on the prospectus cover as underwriters. The filing says Attovia has applied to list on Nasdaq, and the offering is contingent on obtaining that approval.

Fu is taking a diagnostic spinout into the public market

Attovia was incorporated in Delaware on December 16th, 2022 and began principal operations in June 2023, according to the S-1. The company came out of Alamar Biosciences and Frazier Life Sciences, with the therapeutic rights to Alamar's Attobody platform moved into a standalone company.

At launch, Alamar and Frazier said Attovia closed a $60 million Series A led by Frazier, with venBio and Illumina Ventures joining. The same announcement named Fu, then a Frazier Life Sciences venture partner, as co-founder and CEO and cited prior leadership roles at Zai Lab, Portola Pharmaceuticals, Bristol Myers Squibb and Johnson & Johnson.

Fu has described the company as a bet that technology first built for protein detection could become a therapeutics engine. In a 2024 Illumina Ventures interview, Fu said Alamar originally developed the technology for high-sensitivity protein detection in diagnostics, before he and Alamar founder Yuling Luo pushed to spin out its therapeutic use. He said the team incubated proof-of-platform projects before formally raising the Series A.

The S-1 sharpens that origin story into a public-market pitch. Attovia says all of its product candidates were internally discovered using ATTOBODY, which it in-licensed from Alamar. The platform is built around biparatopic biologics: each ATTOBODY consists of two VHH domains, also known as nanobodies, connected by a proprietary peptide-based linker and selected through an evolution-driven, high-throughput process.

The company says it has completed over 15 ATTOBODY campaigns against cytokines, cell-surface molecules and multi-transmembrane proteins, with what it calls a 100% success rate in discovering individual ATTOBODIES and complex biologics meeting desirable preclinical characteristics. That is Attovia's claim, and it is still mostly a preclinical platform claim. The investment case now turns on whether the first clinical program can convert those discovery assertions into patient data.

The first asset is an itch drug candidate

Attovia's lead candidate, ATTO-1310, targets interleukin-31, a pathway associated with itch. The company says dosing was completed in a Phase 1 clinical trial in healthy volunteers and patients in the first quarter of 2026. ATTO-1310 is being studied for chronic pruritus and high-itch atopic dermatitis, and Attovia says it may later evaluate the candidate in chronic pruritus of unknown origin, cholestatic pruritus in primary biliary cholangitis and primary sclerosing cholangitis, and chronic kidney disease-associated pruritus.

The prospectus describes initial Phase 1b data as showing rapid, deep itch relief in chronic pruritus and high-itch atopic dermatitis patients, along with lesion control in high-itch atopic dermatitis. Attovia also says ATTO-1310 has shown a favorable tolerability profile to date, with predominantly Grade 1 or Grade 2 treatment-emergent adverse events and no treatment-related serious or severe adverse events observed. Those are company-reported, early-stage data from an incomplete development path, and the S-1 itself says Attovia has not completed any clinical trials.

The second candidate, ATTO-2306, is a bispecific targeting IL-13 and IL-31. It is in IND-enabling studies, and Attovia expects to begin a Phase 1 clinical trial in the first half of 2027. The third named candidate, ATTO-1091, is a trispecific Fc-fusion protein designed to block TL1A, IL-23 and integrin alpha4beta7 for inflammatory bowel disease; Attovia also expects to begin a randomized, placebo-controlled Phase 1 trial in the first half of 2027, subject to IND clearance.

The timing explains why Attovia is heading to market now. Its lead program has moved into humans, the next two candidates are queued for first-in-human studies, and the company is about to enter the cash-intensive stretch where a platform story becomes a clinical-trial budget. Attovia had 44 full-time employees as of June 30th, 2026. At March 31st, 2026, it had $43.3 million in cash and cash equivalents and $89.3 million in marketable securities, according to the prospectus.

The company has no product revenue and widening losses

Attovia's revenue line is still incidental to its drug pipeline. The company says it recognized $1.4 million of collaboration revenue in 2025 related to an EndPath radioligand agreement and has not generated any revenue from product sales. It says it does not expect product revenue unless and until its candidates advance through clinical development and regulatory approval, if ever.

Losses are already moving in the other direction. Attovia reported net losses of $39.8 million in 2024 and $60.6 million in 2025. For the three months ended March 31st, 2026, it reported a net loss of $18.7 million, compared with $15.2 million in the same period a year earlier. Its accumulated deficit was $129.7 million as of March 31st, 2026.

R&D is the main driver. Research and development expense rose from $33.9 million in 2024 to $54.2 million in 2025, with Attovia attributing a $15.7 million increase in clinical, manufacturing and preclinical services largely to CRO and CMO activity tied to ATTO-1310, ATTO-3712 and ATTO-1091 development.

The filing is candid about the limits of the story. Attovia says it has a limited operating history, has not completed any clinical trials, has no products approved for commercial sale, has incurred significant operating losses since inception and expects to incur significant losses for the foreseeable future. It also says it may never achieve or maintain profitability and will require substantial additional capital even if the IPO succeeds.

For Fu, the Nasdaq filing is a clean founder-market moment. Attovia was created to pull a platform out of a diagnostics company, assemble a drug-development team around it and move fast enough to show a clinical foothold before the private balance sheet became the bottleneck. Public investors are now being asked to fund the next proof point without the usual late-stage biotech comfort of pivotal data or a near-term commercial product.

That is the trade in the prospectus: three internally discovered candidates, one early human trial and a platform the company says can produce multispecific biologics quickly, set against blank IPO terms, no product revenue and an R&D bill that is only starting to scale.